FTC Clears Pfizer's $2.4B Capsugel Sale To KKR
The FTC granted early termination of the antitrust review of the deal, finding that KKR’s purchase of the leading hard capsule manufacturer poses no threat to competition in the drug delivery sector.
"We’re pleased to have received FTC approval for the transaction," Pfizer spokeswoman Joan Campion said. "We continue to expect the transaction to close in the third quarter 2011."...
To view the full article, register now.